Ha, tell me about it I am one of the same. Except, new CEO and just whats shown on the clinical pipeline - this clinical trial can lead to sales effectively. It is pretty exciting + combo results to then hopefully get a trial run up in ambulant population will be great.
the comparable buyout assets have crazy figures. We are P2, its just farcical we are market cap of < $50M.
Ann: Antisense Therapeutics Corporate Presentation, page-6
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $121.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15269 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 37037 | 1 |
View Market Depth
| Last trade - 16.12pm 16/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable